<DOC>
	<DOCNO>NCT02937012</DOCNO>
	<brief_summary>The primary biliary cholangitis ( PBC ) , formerly know primary biliary cirrhosis , treatment base use ursodeoxycholic acid ( UDCA ) daily dose 13 15 mg/kg , without treatment option . Patients good complete response UDCA liver transplant-free survival delay histologic progression compare patient partial response . Nowadays estimate partial response UDCA approximately 30 50 % patient PBC . There need new second line management strategy patient without biochemical response UDCA . The addition bezafibrate treatment PBC patient partial biochemical response UDCA , increase biochemical response improve long term prognosis ? And , efficacy security bezafibrate PBC patient without biochemical response ?</brief_summary>
	<brief_title>Use Bezafibrate Patients With Primary Biliary Cirrhosis Archive Complete Biochemical Response Non-responders</brief_title>
	<detailed_description>There case report pilot study patient primary biliary cholangitis ( PBC ) In literature effect fibrates ( specially bezafibrate ) improvement biochemical cholestasis see , however clinical benefit ( survival , mortality , fatigue , pruritus ) report likewise response criterion use previous study heterogeneous . In previous study , bezafibrate proved secure drug patient , adverse event , also economic easy access drug . For investigator intent study utility bezafibrate additional treatment PBC patient without response UDCA . This randomized , placebo-controlled , parallel-group study design enroll total 34 patient diagnosis PBC without complete response use UDCA year , participant divide randomization receive bezafibrate placebo , result total two group 17 patient . Both group follow every 3 month total 1 year clinical laboratory follow-up determine efficacy security treatment . The investigator measure laboratory variable relate disease possible adverse effect use fibrates ( creatine kinase , transaminase , bilirubin , alkaline phosphatase ) , also investigator measure quality life variable ( pruritus severity , Short Form [ SF ] -36 questionnaire ) , determine fibrosis stage begin end study non-invasive method ( transient elastography ) . The study direct patient PBC diagnosis management standard UDCA dose ( 13 15 mg/kg per day ) least 6 month reach complete biochemical response , define Paris II criterion . The dose fibrate use bezafibrate 200 mg every 12 hour placebo every 12 hour 12 month , exact characteristic avoid recognition . Patients continue administration UDCA dose enrollment . The intervention period 12 month , follow-up every 3 month complete 5 medical follow-up visit ( 0 , 3 , 6 , 9 12 month ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<mesh_term>Bezafibrate</mesh_term>
	<criteria>Primary biliary cirrhosis diagnosis make 2 3 criterion : 1 . Biochemical evidence cholestasis alkaline phosphatase rise 1.5 time upper normal limit . 2 . Antimitochondrial antibody positivity 3 . Histopathologic evidence nonsuppurative cholangitis small bile duct destruction Use ursodeoxycholic acid ( UDCA ) least 6 month enrollment therapeutic dose ( 13 15 mg per Kg per day ) Evidence suboptimal biochemical response UDCA , define presence one Paris II criterion : 1 . Alkaline phosphatase equal 1.5 time normal upper limit 2 . Aspartate transaminase equal 1.5 time normal upper limit 3 . Bilirubin 1 mg/dL Signed informed consent . No informed consent give enrollment Actual history hepatic decompensation ( ascitis , variceal upper gastrointestinal bleeding , hepatic encephalopathy ) Secondary immunosuppression cause drug ( example ; steroid ) , use statins fibrates last 6 month . The investigator exclude patient medical indication statin use . Coexistence hepatopathy , chronic viral infection like C hepatitis virus , B virus HIV . Excessive alcohol intake , autoimmune hepatitis , nonalcoholic fatty liver disease ( diagnosed histopathology ) , Wilson disease , hemochromatosis , celiac disease , choledocolithiasis , noncontrolled thyroid disease Post liver transplant Known allergy intolerance fibrates Pregnancy woman desire become pregnant Chronic kidney disease glomerular filtration le 60 ml/min Patients total anticoagulation vitamin K antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Primary Biliary Cirrhosis</keyword>
	<keyword>Primary Biliary Cholangitis</keyword>
	<keyword>Bezafibrate</keyword>
	<keyword>Ursodeoxycholic acid</keyword>
</DOC>